Compare XBIT & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | ELA |
|---|---|---|
| Founded | 2005 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.0M | 449.7M |
| IPO Year | 2015 | 1995 |
| Metric | XBIT | ELA |
|---|---|---|
| Price | $2.55 | $17.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 26.4K | ★ 69.1K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 115.38 |
| EPS | N/A | ★ 0.56 |
| Revenue | N/A | ★ $241,021,362.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.54 |
| P/E Ratio | ★ N/A | $31.71 |
| Revenue Growth | N/A | ★ 33.62 |
| 52 Week Low | $2.09 | $5.33 |
| 52 Week High | $3.61 | $18.98 |
| Indicator | XBIT | ELA |
|---|---|---|
| Relative Strength Index (RSI) | 67.38 | 64.78 |
| Support Level | $2.15 | $16.09 |
| Resistance Level | $2.69 | $18.29 |
| Average True Range (ATR) | 0.07 | 0.79 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 84.38 | 62.68 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.